BACKGROUND: With the increased effectiveness of anticancer therapy, much more attention is being paid to the monitoring of the side-effects of chemotherapy, which often constitute a limiting factor in anticancer therapy. In this pilot study, the results of our monitoring of changes in cardio-specific markers and thyroid gland parameters in patients with colorectal carcinoma in the course of adjuvant and palliative chemotherapy are presented. PATIENTS AND METHODS: A total of 42 patients with colorectal carcinoma were monitored (median age 52 years, range 34-82 years); in these patients a post-operative adjuvant or palliative chemotherapy was applied (de Gramont's or FOLFIRI regimen). In all of these patients, the cardio-specific markers brain natriuretic peptide (BNP) and troponin I were assessed, as well as markers of thyroid gland function, TSH and FT4. RESULTS: In the course of chemotherapy, more than half of the patients showed laboratory signs of coronary ischemia; in 6 of these (14%) coronary ischemia was manifested with troponin I levels above 0.3 microg/L. Twenty patients (48%) had laboratory signs of heart failure in the course of adjuvant or palliative chemotherapy. A more frequent incidence of elevated cardio-specific enzymes was observed in continual regimens than in bolus application of fluorouracil. Reduced TSH values were observed in the course of chemotherapy in 9 patients (21%), without changes in FT4 values. An increase in TSH values was observed in 4 patients (10%), again without changes in FT4 values. CONCLUSION: The pilot study demonstrated that in patients undergoing treatment for colorectal carcinoma by adjuvant or palliative chemotherapy on the basis of 5-fluorouracil, it is advisable to check for possible cardiotoxicity and simultaneously to monitor thyroid gland functions. This systematic monitoring may improve the quality of life in cancer patients.

Departments of Oncology University Hospital and Medical Faculty Pilsen Charles University Prague Czech Republic

000      

00000naa 2200000 a 4500

001      

bmc10000919

003      

CZ-PrNML

005      

20111210154823.0

008      

100115s2007 gr e eng||

009      

AR

040    __

$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a gr

100    1_

$a Holubec, Luboš, $d 1972- $7 xx0068645

245    10

$a Dynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients--a pilot study / $c Holubec L Jr, Topolcan O, Finek J, Salvet J, Svoboda T, Svobodova S, Mrazkova P, Ludvikova M

314    __

$a Departments of Oncology, University Hospital and Medical Faculty Pilsen, Charles University Prague, Czech Republic. holubec@fnplzen.cz

520    9_

$a BACKGROUND: With the increased effectiveness of anticancer therapy, much more attention is being paid to the monitoring of the side-effects of chemotherapy, which often constitute a limiting factor in anticancer therapy. In this pilot study, the results of our monitoring of changes in cardio-specific markers and thyroid gland parameters in patients with colorectal carcinoma in the course of adjuvant and palliative chemotherapy are presented. PATIENTS AND METHODS: A total of 42 patients with colorectal carcinoma were monitored (median age 52 years, range 34-82 years); in these patients a post-operative adjuvant or palliative chemotherapy was applied (de Gramont's or FOLFIRI regimen). In all of these patients, the cardio-specific markers brain natriuretic peptide (BNP) and troponin I were assessed, as well as markers of thyroid gland function, TSH and FT4. RESULTS: In the course of chemotherapy, more than half of the patients showed laboratory signs of coronary ischemia; in 6 of these (14%) coronary ischemia was manifested with troponin I levels above 0.3 microg/L. Twenty patients (48%) had laboratory signs of heart failure in the course of adjuvant or palliative chemotherapy. A more frequent incidence of elevated cardio-specific enzymes was observed in continual regimens than in bolus application of fluorouracil. Reduced TSH values were observed in the course of chemotherapy in 9 patients (21%), without changes in FT4 values. An increase in TSH values was observed in 4 patients (10%), again without changes in FT4 values. CONCLUSION: The pilot study demonstrated that in patients undergoing treatment for colorectal carcinoma by adjuvant or palliative chemotherapy on the basis of 5-fluorouracil, it is advisable to check for possible cardiotoxicity and simultaneously to monitor thyroid gland functions. This systematic monitoring may improve the quality of life in cancer patients.

650    _2

$a financování organizované $7 D005381

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $7 D000971

650    _2

$a adjuvantní chemoterapie $x škodlivé účinky $7 D017024

650    _2

$a kolorektální nádory $x farmakoterapie $7 D015179

650    _2

$a fluorouracil $x aplikace a dávkování $x škodlivé účinky $7 D005472

650    _2

$a srdce $x účinky léků $7 D006321

650    _2

$a srdeční selhání $x chemicky indukované $7 D006333

650    _2

$a lidé $7 D006801

650    _2

$a lidé středního věku $7 D008875

650    _2

$a ischemická choroba srdeční $x chemicky indukované $7 D017202

650    _2

$a natriuretický peptid typu B $x účinky léků $7 D020097

650    _2

$a paliativní péče $7 D010166

650    _2

$a pilotní projekty $7 D010865

650    _2

$a štítná žláza $x účinky léků $7 D013961

650    _2

$a thyreotropin $x účinky léků $7 D013972

650    _2

$a thyroxin $x účinky léků $7 D013974

650    _2

$a troponin I $x škodlivé účinky $7 D019210

700    1_

$a Topolčan, Ondřej, $d 1943- $7 jn20000402383

700    1_

$a Fínek, Jindřich, $d 1957- $7 xx0026897

700    1_

$a Salvét, Jiří $7 xx0129316

700    1_

$a Svoboda, Tomáš, $d 1968 červenec 12.- $7 xx0137055

700    1_

$a Svobodová, Šárka $7 xx0104598

700    1_

$a Mrázková, Petra, $d 1969- $7 skuk0000937

700    1_

$a Ludvíková, Marie, $d 1956- $7 xx0073926

773    0_

$w MED00000478 $t Anticancer research $g Roč. 27, č. 4A (2007), s. 1883-1886 $x 0250-7005

910    __

$a ABA008 $b x $y 8

990    __

$a 20100114083259 $b ABA008

991    __

$a 20100211151956 $b ABA008

999    __

$a ok $b bmc $g 703647 $s 566088

BAS    __

$a 3

BMC    __

$a 2007 $b 27 $c 4A $d 1883-1886 $i 0250-7005 $m Anticancer research $x MED00000478

LZP    __

$a 2010-b1/vtme